Andrew Grottick, Ph.D.

Vice President, CNS Drug Discovery


Andy Grottick has 20 years of drug discovery experience in the pharmaceutical industry in both Europe and the US, most recently at Arena Pharmaceuticals in San Diego as the Head of CNS Drug Discovery. In this role he was the in vivo pharmacology lead on the 5-HT2C agonist project which produced Belviq, working on the project from first dosing in vivo through regulatory approval in the US. Andy worked collaboratively on projects with other companies, including Eli Lilly and Taisho, and led and supported a number of other programs into preclinical and clinical development. This included orphan GPCR targets, one of which was partnered with a major pharmaceutical company. Prior to Arena, Andy worked in the CNS department at Hoffman-La Roche in Basel, Switzerland.

Andy trained as a behavioral pharmacologist in London, studying for his Ph.D. at both London Guildhall University and the UCL Institute of Neurology in Queen’s Square, London.